We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances inclu... Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies. Show more
false 0001813814 0001813814 2024-03-07 2024-03-07 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORTPursuant to...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health...
false 0001813814 0001813814 2024-03-07 2024-03-07 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORTPursuant to...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health...
As filed with the Securities and Exchange Commission on March 7, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...
false 0001813814 0001813814 2024-03-07 2024-03-07 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORTPursuant to...
-A single oral administration of MM120 100 µg met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65...
="/Images/box-checked.jpg" alt="Checkbox checked">144: Remarks and SignatureRemarksDate of Notice03/01/2024ATTENTION: The person for whose account the securities to which this notice relates are...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.52 | -5.18962075848 | 10.02 | 10.84 | 9.33 | 2733692 | 9.90235819 | CS |
4 | 4.01 | 73.0418943534 | 5.49 | 11.1 | 5.47 | 4489956 | 9.01004738 | CS |
12 | 5.9 | 163.888888889 | 3.6 | 11.1 | 3.49 | 2015879 | 7.95767775 | CS |
26 | 5.98 | 169.886363636 | 3.52 | 11.1 | 2.41 | 1206494 | 6.89222159 | CS |
52 | 6.59 | 226.4604811 | 2.91 | 11.1 | 2.41 | 853981 | 6.01681872 | CS |
156 | -75.8005 | -88.8629023277 | 85.3005 | 86.55 | 2.12 | 3308414 | 28.06543821 | CS |
260 | -75.8005 | -88.8629023277 | 85.3005 | 86.55 | 2.12 | 3308414 | 28.06543821 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions